Statement about PBS listing of FASENRA (benralizumab) PEN and NUCALA (mepolizumab).
FASENRA (benralizumab) and NUCALA (mepolizumab) now available on PBS
Fasenra (benralizumab) and Nucala (mepolizumab) – are now available on the pharmaceutical benefits scheme (PBS) in a pre-filled pen device form for the treatment of severe eosinophilic asthma (EA).
A pre-filled pen is a disposable, spring-loaded medical device designed to deliver a specific dose of a medicine via injection.
Although the medications themselves were already subsidised, the listing of these medications in a pre-filled pen form is new and a significant step for people with severe asthma, especially those who are empowered to self-administer their medication at home.
Asthma Australia CEO Michele Goldman said the reimbursement represents a step forward in reducing the burden of severe asthma on patients, their families and the healthcare system.
“The impact of severe asthma on the quality of life of patients and their families can be enormous,” Ms Goldman said.
“Frequent visits to a healthcare professional to administer treatment can be an added challenge for these patients.
“Innovations around self-treatment options may contribute towards helping patients with severe eosinophilic asthma reduce the burden of treatment on their lives and the overall burden on the healthcare system.”
For further information on Fasenra Pen, please visit: https://bit.ly/2AYiTje
For further information on Nucala, please visit: https://bit.ly/2ASpkUM